Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is not associated with an increased risk for thyroid cancer over the ...

For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduc ...

Insights from a study on GLP-1 receptor agonists reveal benefits for cardiometabolic health, with notable risks for ...

People who take weight-loss drugs based on GLP-1 receptor agonists seem to have reduced risk for a litany of diseases, ...

Health-care companies rose after more promising data for the best-selling Glucagon-like Peptide inhibitor drugs. Shares of Novo Nordisk and Eli Lilly, the two leading producers of GLP-1 drugs, rallied ...

Glucagon-like peptide-1 receptor agonists (GLP-1RAs), used to treat diabetes and for weight loss, may be linked with a reduced risk of substance use and neurocognitive disorders, a US study in people ...

Computational research conducted by scientists from Washington University in St. Louis shows that GLP-1 agonists can have ...

A new study has considered some of the potential benefits and risks of glucagon-like peptide 1 receptor agonists (GLP-1RAs), ...

Rybelsus (semaglutide) is the first GLP-1 agonist drug that can be dosed orally ... (crisaborole), a topical phosphodiesterase 4 (PDE-4) inhibitor for atopic dermatitis already sold as Eucrisa ...

Former Trump administration health official Joe Grogan applauds Biden proposal that Medicare and Medicaid cover GLP-1 weight ...

The following is a summary of “Association between incretin-based drugs and risk of cholangiocarcinoma among patients with ...

1 GLP-1 muscle loss: the Company recently announced ... obesity costs the U.S. healthcare system nearly $173 billion annually. 3 TNF inhibitor drug category: the global market value for TNF ...